Profound Medical Corp. (PROF)
- Previous Close
7.70 - Open
7.85 - Bid 5.56 x 200
- Ask 7.99 x 100
- Day's Range
7.63 - 7.99 - 52 Week Range
7.11 - 15.49 - Volume
10,017 - Avg. Volume
39,709 - Market Cap (intraday)
195.187M - Beta (5Y Monthly) 0.79
- PE Ratio (TTM)
-- - EPS (TTM)
-1.35 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
12.61
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
www.profoundmedical.comRecent News: PROF
Performance Overview: PROF
Trailing total returns as of 4/24/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PROF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PROF
Valuation Measures
Market Cap
192.56M
Enterprise Value
174.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
23.51
Price/Book (mrq)
6.26
Enterprise Value/Revenue
24.21
Enterprise Value/EBITDA
-6.51
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.02%
Return on Equity (ttm)
-68.69%
Revenue (ttm)
7.2M
Net Income Avi to Common (ttm)
-28.57M
Diluted EPS (ttm)
-1.35
Balance Sheet and Cash Flow
Total Cash (mrq)
26.21M
Total Debt/Equity (mrq)
25.47%
Levered Free Cash Flow (ttm)
-13.4M